Cyclosporine is used extensively in kidney transplantation and is a substrate for cytochrome P450 enzymes. The role of cytochrome p450 polymorphisms in kidney transplant outcome has not yet been fully elucidated. We investigate the clinical impact of single nucleotide polymorphisms in CYP3A4, CYP3A5, PPARα, and POR*28 in 255 kidney transplant recipients. We examine for any association with graft survival, time to first cancer, and delayed graft function, and also measure cyclosporine levels at days 3, 10, and months 1, 3, 6, and 12 after transplantation. The CYP3A4*22 allele is significant associated with the development of cancer post-kidney transplantation (HR 0.20, 95% CI 0.07-0.57, p = 0.003). It is not significantly associated with graft survival. No other SNP's were associated with graft survival time to first cancer, or delayed graft function. There was a non-significant trend of lower cyclosporine dose requirement in CYP3A4*22 carriers. Independent replication of our findings is now warranted to confirm or reject the role of CYP3A variants in cancer development following kidney transplantation.
P.B. Danielson Bentham Science Publisher, The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans, 10.2174/1389200023337054
Hariharan Sundaram, Johnson Christopher P., Bresnahan Barbara A., Taranto Sarah E., McIntosh Matthew J., Stablein Donald, Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996, 10.1056/nejm200003023420901
Schiff J., Cole E., Cantarovich M., Therapeutic Monitoring of Calcineurin Inhibitors for the Nephrologist, 10.2215/cjn.03791106
Lamba Jatinder K, Lin Yvonne S, Schuetz Erin G, Thummel Kenneth E, Genetic contribution to variable human CYP3A-mediated metabolism, 10.1016/s0169-409x(02)00066-2
Wang D, Guo Y, Wrighton S A, Cooke G E, Sadee W, Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, 10.1038/tpj.2010.28
Engels Eric A., Pfeiffer Ruth M., Fraumeni Joseph F., Kasiske Bertram L., Israni Ajay K., Snyder Jon J., Wolfe Robert A., Goodrich Nathan P., Bayakly A. Rana, Clarke Christina A., Copeland Glenn, Finch Jack L., Fleissner Mary Lou, Goodman Marc T., Kahn Amy, Koch Lori, Lynch Charles F., Madeleine Margaret M., Pawlish Karen, Rao Chandrika, Williams Melanie A., Castenson David, Curry Michael, Parsons Ruth, Fant Gregory, Lin Monica, Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients, 10.1001/jama.2011.1592
Moloney F.J., Comber H., O'Lorcain P., O'Kelly P., Conlon P.J., Murphy G.M., A population-based study of skin cancer incidence and prevalence in renal transplant recipients, 10.1111/j.1365-2133.2005.07021.x
Laing Mary E., Dicker Patrick, Moloney Fergal J., Ho Wen L., Murphy Gillian M., Conlon Peter, Whitehead Alexander S., Shields Denis C., Association of Methylenetetrahydrofolate Reductase Polymorphism and the Risk of Squamous Cell Carcinoma in Renal Transplant Patients : , 10.1097/01.tp.0000266069.41882.28
O'Brien Robert P., Phelan Paul J., Conroy Judith, O'Kelly Patrick, Green Andrew, Keogan Mary, O'Neill Derek, Jennings Susan, Traynor Carol, Casey Jillian, McCormack Mark, Conroy Ronan, Chubb Anthony, Ennis Sean, Shields Denis C., Cavalleri Gianpiero L., Conlon Peter J., A genome-wide association study of recipient genotype and medium-term kidney allograft function, 10.1111/ctr.12093
Elens L., Bouamar R., Hesselink D. A., Haufroid V., van der Heiden I. P., van Gelder T., van Schaik R. H. N., A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients, 10.1373/clinchem.2011.165613
Elens Laure, van Schaik Ron H, Panin Nadtha, de Meyer Martine, Wallemacq Pierre, Lison Dominique, Mourad Michel, Haufroid Vincent, Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients, 10.2217/pgs.11.90
Elens L, Pharmacogenet Genomics, 22, 373 (2012)
Zhou Li-Ping, Yao Fan, Luan Hong, Wang Yin-Ling, Dong Xi-Hua, Zhou Wen-Wen, Wang Qi-Hui, CYP3A4*1B polymorphism and cancer risk: A HuGE review and meta-analysis, 10.1007/s13277-012-0592-z
Farrugia Daniela, Mahboob Sophia, Cheshire James, Begaj Irena, Khosla Sajan, Ray Daniel, Sharif Adnan, Malignancy-related mortality following kidney transplantation is common, 10.1038/ki.2013.458
de Arriba Gabriel, Calvino Miryam, Benito Selma, Parra Trinidad, Cyclosporine A-induced apoptosis in renal tubular cells is related to oxidative damage and mitochondrial fission, 10.1016/j.toxlet.2013.01.007
Moore J., McKnight A. J., Dohler B., Simmonds M. J., Courtney A. E., Brand O. J., Briggs D., Ball S., Cockwell P., Patterson C. C., Maxwell A. P., Gough S. C. L., Opelz G., Borrows R., Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure, 10.1681/asn.2012030260
Gervasini Guillermo, Garcia Montserrat, Macias Rosa María, Cubero Juan Jose, Caravaca Francisco, Benitez Julio, Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation : Pharmacogenetics of tacrolimus, 10.1111/j.1432-2277.2012.01446.x
Gijsen Violette, Mital Seema, van Schaik Ron H., Soldin Offie P., Soldin Steven J., van der Heiden Ilse P., Nulman Irena, Koren Gideon, de Wildt Saskia N., Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients, 10.1016/j.healun.2011.08.001
Bibliographic reference
Traynor, Carol ; Conlon, Peter ; Phelan, Paul J ; O'Kelly, Patrick ; Elens, Laure ; et. al. Association of CYP3A variants with kidney transplant outcomes.. In: Renal Failure, Vol. 37, no. 4, p. 562-566 (2015)
